Glucocorticoid receptor antagonism by cyproterone acetate and RU486.

The steroid compound cyproterone acetate was identified in a high-throughput screen for glucocorticoid receptor (GR) binding compounds. Cyproterone (Schering AG) is clinically used as an antiandrogen for inoperable prostate cancer, virilizing syndromes in women, and the inhibition of sex drive in men. Despite its progestin properties, cyproterone shares a similar pharmacological profile with the antiprogestin mifepristone (RU486; Roussel Uclaf SA). The binding affinities of cyproterone and RU486 for the GR and progesterone receptor were similar (K(d), 15-70 nM). Both compounds were characterized as competitive antagonists of dexamethasone without intrinsic transactivating properties in rat hepatocytes (K(i), 10-30 nM). In osteosarcoma cells, RU486 revealed a higher potency than cyproterone acetate to prevent responses to dexamethasone-induced GR transactivation and NF kappa B transrepression. Upon administration to Sprague-Dawley rats, both compounds were found to be orally bioavailable and to inhibit transactivation of liver GR. Molecular docking of cyproterone acetate and RU486 into the homology model for the GR ligand binding domain illustrated overlapping steroid scaffolds in the binding pocket. However, in contrast to RU486, cyproterone lacks a bulky side chain at position C11 beta that has been proposed to trigger active antagonism of nuclear receptors by displacing the C-terminal helix of the ligand-binding domain, thereby affecting activation function 2. Cyproterone may therefore inhibit transactivation of the GR by a molecular mechanism recently described as passive antagonism. New therapeutic profiles may result from compounds designed to selectively stabilize the inactive and active conformations of certain nuclear receptors.

[1]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[2]  F. Neumann.  The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. , 2009, Experimental and clinical endocrinology.

[3]  E. Baulieu,et al.  RU486 (mifepristone): mechanisms of action and clinical uses. , 1997, Annual review of medicine.

[4]  István Kolossváry,et al.  Low‐mode conformational search elucidated: Application to C39H80 and flexible docking of 9‐deazaguanine inhibitors into PNP , 1999 .

[5]  N. Genov,et al.  Effect of hormone replacement therapy on insulin secretion and insulin sensitivity in postmenopausal diabetic women , 2002, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[6]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[7]  I. Vauhkonen,et al.  Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. , 2000, The Journal of clinical endocrinology and metabolism.

[8]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Thompson,et al.  Overexpression of full-length human glucocorticoid receptor in Spodoptera frugiperda cells using the baculovirus expression vector system. , 1990, Molecular endocrinology.

[10]  J. Fagart,et al.  The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. , 1995, Endocrinology.

[11]  S. Hayashi,et al.  Tyrosine aminotransferase. Purificaton and characterization. , 1967, The Journal of biological chemistry.

[12]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[13]  D. Granner,et al.  [80] Tyrosine aminotransferase (rat liver)☆☆☆ , 1970 .

[14]  T. I. Diamondstone.  Assay of tyrosine transaminase activity by conversion of p-hydroxyphenylpyruvate to p-hydroxybenzaldehyde☆ , 1966 .

[15]  P. Chambon,et al.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. , 1995, Nature.

[16]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[17]  David A. Agard,et al.  Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism , 2002, Nature Structural Biology.

[18]  P. Sigler,et al.  Atomic structure of progesterone complexed with its receptor , 1998, Nature.

[19]  István Kolossváry,et al.  Low Mode Search . An Efficient , Automated Computational Method for Conformational Analysis : Application to Cyclic and Acyclic Alkanes and Cyclic Peptides , 1997 .

[20]  F. Labrie,et al.  Androgen receptor antagonists (antiandrogens): structure-activity relationships. , 2000, Current medicinal chemistry.

[21]  P. Chambon,et al.  Mechanisms of antihormone action , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[23]  G. Teutsch,et al.  Design of ligands for the glucocorticoid and progestin receptors. , 1991, Biochemical Society transactions.

[24]  C. Kellendonk,et al.  Genetic dissection of glucocorticoid receptor function in mice. , 1999, Current opinion in genetics & development.

[25]  F. A. Neugebauer,et al.  Electrochemical oxidation and structural changes of 5,6-dihydrobenzo[c]cinnolines , 1996 .

[26]  K. Kaestner,et al.  DNA Binding of the Glucocorticoid Receptor Is Not Essential for Survival , 1998, Cell.

[27]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[28]  R. Sapolsky,et al.  How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. , 2000, Endocrine reviews.

[29]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[30]  M. Karin.  New Twists in Gene Regulation by Glucocorticoid Receptor: Is DNA Binding Dispensable? , 1998, Cell.

[31]  D. Faulds,et al.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. , 1994 .

[32]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[33]  H. Gronemeyer,et al.  Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.

[34]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.